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Abstract
Angiotensin-converting enzyme 2 (ACE2) is the primary enzyme of the vasoprotective axis of the 
renin angiotensin system (RAS). We tested the hypothesis that loss of ACE2 would exacerbate 
diabetic retinopathy by promoting bone marrow dysfunction. ACE2-/y were crossed with Akita 
mice, a model of type 1 diabetes. When comparing the bone marrow of the ACE2-/y-Akita mice to 
that of Akita mice, we observed a reduction of both short-term and long-term repopulating 
hematopoietic stem cells, a shift of hematopoiesis towards myelopoiesis, and an impairment of 
lineage-c-kit+ hematopoietic stem/progenitor cell (HS/PC) migration and proliferation. Migratory 
and proliferative dysfunction of these cells was corrected by exposure to angiotensin-1–7 (Ang-1–
7), the protective peptide generated by ACE2. Over the duration of diabetes examined, ACE2 
deficiency led to progressive reduction in electrical responses assessed by electroretinography and 
to increases in neural infarcts observed by fundus photography. Compared to Akita mice, ACE2-/y-
Akita at 9-months of diabetes showed an increased number of acellular capillaries indicative of 
more severe diabetic retinopathy. In diabetic and control human subjects, CD34+ cells, a key bone 
marrow HS/PC population, were assessed for changes in mRNA levels for MAS, the receptor for 
Ang-1–7. Levels were highest in CD34+ cells from diabetics without retinopathy. Higher serum 
Ang-1–7 levels predicted protection from development of retinopathy in diabetics. Treatment with 
Ang-1–7 or alamandine restored the impaired migration function of CD34+ cells from subjects 
with retinopathy. These data support that activation of the protective RAS within HS/PCs may 
represent a therapeutic strategy for prevention of diabetic retinopathy.
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Introduction
Hyperactivity of the vasodeleterious arm (Angiotensin-Converting Enzyme (ACE)/
angiotensin II (Ang II)/AT1 receptor) of the RAS has been implicated in the pathogenesis of 
a wide range of diseases that include diabetic retinopathy and nephropathy, as well as 
cardiovascular disease [1, 2]. ACE2 converts Ang II to Ang-1–7 which, by virtue of its 
actions on the MAS receptor, opposes the effects of Ang II and is therefore considered the 
protective arm of RAS (ACE2/Ang-1–7/Mas). Ang-1–7 mediates its beneficial effects by 
reducing inflammation and oxidative stress [3, 4].
The existence of specific RAS systems in organs including the bone marrow has been well-
established [5–13]. Local RAS is active in primitive embryonic hematopoiesis [14, 15] and 
continues to regulate each stage of physiological and pathological blood cell production in 
the adult via autocrine, paracrine, and intracrine pathways [16]. ACE degrades the inhibitory 
tetrapeptide N-Acetyl-Ser-Asp-Lys-Pro and triggers primitive stem cells into S phase [17]. 
Ang II activates AT1 to stimulate the JAK-STAT pathway promoting hematopoiesis [9, 18]. 
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Local RAS peptides directly regulate myelopoiesis [19], erythropoiesis [20], thrombopoiesis 
and the development of other cellular lineages [21–23].
Previously, we showed that diabetic individuals who maintain ACE2 mRNA levels in CD34+ 
cells do not develop diabetic retinopathy [1, 24–29]. We also showed that ACE inhibitors, 
which are known to increase ACE2 levels, function to hinder the development of diabetes-
induced bone marrow dysfunction and myeloidosis in streptozotocin-injected rats [30, 31].
In this study, we examined the impact of chronic ACE2 loss on hematopoiesis and 
microvascular dysfunction in type 1 diabetes by breeding ACE2-/y mice to Akita mice. We 
hypothesized that chronic loss of ACE2 would dramatically impact hematopoiesis and 
promote diabetic retinopathy in murine models and in humans.
Materials and methods
Animals
All animal procedures were approved by the Institutional Animal Care and Use Committee 
(animal protocol # 11165) at the Indiana University School of Medicine. Wild type (WT; 
genotype: ACE2+/y-Ins2WT/WT), Akita (genotype: ACE2+/y-Ins2WT/C96Y), ACE2 knockout 
(ACE2-/y; genotype: ACE2-/y-Ins2WT/WT), and ACE2-/y-Akita (genotype: ACE2-/y-
Ins2WT/C96Y) mice were generated as described elsewhere [32]. All mice were on the same 
C57BL/6J background. Only males were used in the study, because Akita male mice are 
reported to display a more severe diabetic phenotype than female mice [33]. Mice were 
housed in the Laboratory Animal Research Center (LARC) at the Indiana University School 
of Medicine. Blood glucose levels were measured using an Accu-Chek Compact Plus 
glucose meter (Roche Diagnostics, Indianapolis, IN). ACE2-/y-Akita, Akita mice showed 
elevated glucose levels at 6 weeks of age, and were studied at 3 and 9 months after the onset 
of diabetes. Age-matched ACE2-/y and WT were used. The mice were anesthetized by 
inhalation of isoflurane and euthanized by cervical dislocation.
Bone marrow Lineage-c-Kit+ (LK) cell isolation
Bone marrow cells were flushed from mouse femurs and tibias using PBS. Lineage-c-Kit+ 
hematopoietic stem/progenitor cells (HS/PC) were selected by lineage negative and c-Kit 
positive selection kits (Catalog # 19856 and 18757, STEMCELL Technology, Vancouver, 
BC, Canada) and EasySepTM magnets following manufacture’s instruction.
Migration assay
Migratory function of HS/PCs was analyzed by measuring their ability to migrate towards 
100 nM CXCL12 (#460-SD-050, R&D Systems, Minneapolis, MN) using the fluorimetric 
QCM 5μM 96-well chemotaxis cell migration assay (5 μM pore size, ECM512, Millipore, 
Temecula, CA) as previously described [25].
Bone marrow LK cell proliferation
Proliferation function was measured using the cell proliferation BrdU ELISA kit 
(#11647229001, Roche) following incubation for 24 hrs. in serum free stemspan media 
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(#09650, STEMCELL Technologies) containing cytokine cocktails (IL-3 20 ng/ml, IL-6 20 
ng/ml and stem cell factor 50 ng/ml) with or without the supplement of 100 nM Ang-1–7, or 
alamandine.
Colony forming unit assay
Ammonium Chloride Solution (ACS) was used to lyse red blood cells within the 
suspensions of bone marrow or blood cells. ACS treated bone marrow or blood cells were 
plated in MethoCultTM GF M3434 (STEMCELL Technologies) and then identified 
following manufacturer’s instructions and as previously described [34].
Electroretinography
Electroretinography (ERG) was performed on mice after overnight dark-adaption using an 
UTAS-E 2000 ERG system (LKC Technologies, MD, USA). Scotopic rod signaling was 
assessed with 10 increasing intensities of white light. Photopic cone signaling was assessed 
with four increasing light intensities as previously described [35].
Optical coherence tomography
Optical coherence tomography (OCT) was performed using an InVivoVue OCT system 
(Bioptigen, Inc., NC) as previously described [36]. Three high-resolution lateral B-scan 
images were obtained in anesthetized mice.
Acellular capillaries quantification
Trypsin digestion of the retina was performed according to a previously published protocol 
[37].
Flow cytometry
Isolated cells were incubated with 5% rat serum for 15 min at 4 °C. The cells were then 
incubated with primary antibody cocktails for 30 min at 4°C in the dark (FITC anti-mouse c-
Kit, Biolegend, Cat# 105806, 1 μl in 50μl cocktail volume; PE anti-mouse CD34, Biolegend, 
Cat# 119308, 2 μl in 50μl cocktail volume; BV421™ anti-mouse lineage cocktail, 
Biolegend, Cat# 133311, 10 μl in 50μl cocktail volume; PE/Cy7 anti-mouse Sca-1, 
Biolegend, Cat# 108114, 1 μl in 50μl cocktail volume; PerCP-eFluor 710 anti-mouse 
CD135, eBioscience, Cat# 46–1351-82, 1 μl in 50μl cocktail volume; APC anti-mouse 
CD16/CD32, eBioscience, Cat# 14–0161-82, 1 μl in 50μl cocktail volume; PE-CF594 anti-
mouse CD127, BD Biosciences, Cat# 562419, 1 μl in 50μl cocktail volume). After washing, 
the cells were then stained with flexible viability dye eFluor 780 (1 ul/ml, eBioscience, San 
Diego, California, USA) for 30 min at 4°C, washed with PBS twice, and fixed with 1% PFA 
for flow cytometry.
Human study
All human studies were approved by the Institutional Review Boards at the University of 
Florida (Study # 535–2011) and Indiana University (Study # 1402550709). Study subjects 
were recruited as healthy controls (n=13) or diabetics (n=39) with either no retinopathy, or 
with different stages of diabetic retinopathy. Subjects were enrolled according to the 
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following criteria: a). Any male or female between the ages of 21– 98 years of age were 
eligible to participate; b) must have carried the diagnosis of diabetes (either type 1 or type 2 
diabetes) or healthy aged control; and c) was willing and able to cooperate with the eye 
exam protocol. The exclusion criteria included: a) subjects with AMD, glaucoma, uveitis, 
known hereditary degenerations or other significant ocular complications other than diabetic 
retinopathy; b) ongoing malignancy; c) cerebral vascular accident or cerebral vascular 
procedure; d) current pregnancy; e) history of organ transplantation; f) presence of a graft (to 
avoid any effect of the graft on inflammatory parameters); g) evidence of ongoing acute or 
chronic infection (HIV, Hepatitis B or C, tuberculosis); and h) subjects with anemia. The 
degree of diabetic retinopathy was assessed using color fundus imaging and fluorescence 
angiography. Peripheral blood was obtained for plasma collection and CD34+ cell isolation.
Measurement of plasma Ang-1–7 levels
Peripheral blood was collected in heparin-coated tubes (#367963, BD Biosciences) and 
placed on ice immediately after collection. Plasma was obtained by centrifugation at 700 g, 
4°C for 20 min and then snap frozen in liquid nitrogen. The samples were sent to Attoquant 
Diagnostics GmbH (Vienna, Austria), where Ang-1–7 levels were quantified using a 
combination of ultra-pressure-liquid chromatography and mass spectrometry (LC-MS/MS) 
[38]. Stable-isotope-labeled internal standard controls were used to correct the peptide 
recovery due to sample preparation for each individual sample.
Enrichment of human CD34+ cells
One hundred and twenty ml of peripheral blood was diluted with PBS (1:1). Then, every 25 
ml-diluted blood sample was gently overlaid on 12.5 ml Ficoll-Paque Plus (Cat. # 17–
1440-02, GE Healthcare) in 50 ml tubes. After centrifugation at 800 g for 30 min, the buffy 
coat was transferred into a new 50 ml tube and washed three times with PBS supplemented 
with 2% FBS and 1 mM EDTA. Peripheral blood mononuclear cells were then enriched for 
CD34+ cells by the human CD34 positive selection Kit (Cat. #18056, StemCell 
Technologies) using EasySep™ magnets. Enriched CD34+ cells were used either for mRNA 
isolation or for migration assay.
Quantitative RT-PCR
Total RNAs were extracted from human CD34+ cells using RNeasy Mini Kit (Qiagen, 
Valenicia, CA). RNA concentration and qualify were determined using Nanodrop (Thermo 
Scientific, Wilmington, DE). cDNAs were synthesized by iScriptTM cDNA synthsis kit 
(BioRad, Pleasanton, CA). Quantitative PCR were performed using SYBR Green (Qiagen, 
Valenicia, CA) with MAS primers (PPH10808A, Qiagen, Germantown, MD). Results were 
expressed as 2^ (delta Ct) *100 relative to their internal controls.
Data Analysis
Data were initially evaluated for normal distribution using JMP 9 software. One-way or two-
way ANOVA followed by an appropriate multiple comparison post hoc test to compare the 
experimental data sets. If data were not normally distributed, Mann Whitney and Kruskal 
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Wallace tests were used. The data sets were considered significantly different if the p value 
amounted to <0.05. Results were expressed as mean ± SE.
Results
Absence of ACE2 caused depletion of short- and long-term repopulating HSCs in diabetic 
bone marrow
ACE2-/y mice exhibited similar random glucose levels as WT mice at the 3-month time point 
(Figure 1A). There was a 2.8-fold increase in glucose levels for the Akita group at 3 months 
of diabetes in comparison with the WT group (Figure 1A). Loss of ACE2 did not increase 
the glucose levels in Akita mice. At the 9-month time point, both Akita and ACE2-/y-Akita 
showed a further increase in glucose levels as compared to 3 months of diabetes; however, 
no significant difference was detected between these two groups (Figure 1A). Akita and 
ACE2-/y-Akita mice showed reduced body weight compared to WT mice at both 3- and 9-
month time points (Figure 1B). Non-diabetic groups (WT and ACE2-/y mice) had an 
increase in their body weights over time, while 9-month diabetic mice (Akita and ACE2-/y-
Akita) showed similar body weights as at 3 months of diabetes (Figure 1B).
Both the long- and short-term repopulating hematopoietic stem cells (HSCs) play a key role 
in maintaining the pool of hematopoietic cells and the balance of differentiated linages. To 
determine the effect of loss of ACE2 on the diabetic bone marrow, we examined the percent 
of HSC in bone marrow of ACE2-/y-Akita mice and age-matched controls using flow 
cytometry (Figure 1C). Compared to Akita mice with three months’ duration of diabetes, the 
ACE2-/y-Akita mice exhibited an increase in short-term repopulating (ST)-HSCs (Lin-/
CD127-/Sca-1+c-kit+/CD34+CD135-) (Figure 1D). However, the percentage of ST-HSCs 
was reduced at the 9-month time point in double mutant mice as compared to both WT and 
Akita mice (Figure 1D) suggesting a possible loss of compensation in the later stages of 
diabetes.
Long-term repopulating (LT)-HSCs (Lin-/CD127-/Sca-1+c-kit+/CD34-CD135-) represent the 
most primitive stem cells. Interestingly, we observed an age-related increase in phenotypic 
LT-HSCs in nondiabetic groups at the 9-month time point when compared to the 3-month 
time point (Figure 1E), which is consistent with reports from other groups [39, 40]. At 9 
months of diabetes, Akita mice showed a 32% reduction in the percentage of phenotypic LT-
HSCs as compared to WT mice. ACE2-/y-Akita mice showed a greater decrease of these 
cells (~46% reduction versus Akita group) (Figure 1E), supporting our observations that loss 
of ACE2 intensifies the diabetic defect. While bone marrow-derived HSCs are released into 
circulation in a circadian pattern and this pattern is disturbed in diabetes [41], we did not 
detect any difference of lineage-c-kit+sca-1+ (LSK) cells between diabetic and nondiabetic 
groups at the one time point we examined (Supplemental Figure 1).
Impairment of HS/PC migration and proliferation in ACE2-/y-Akita mice
Proliferation and migration of HS/PCs are critical for their mobilization from the bone 
marrow and homing to areas of injury. We next asked whether loss of ACE2 affected these 
key functions of HS/PCs. Akita mice demonstrated reduced lineage- c-Kit+ (LK) cell 
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proliferation at 3 months of diabetes (Figure 2A). Absence of ACE2 worsened the diabetes-
mediated impairment of proliferation at both early and late stages of diabetes (Figure 2A). 
However, when the cells were treated with either Ang-1–7 or alamandine, two vasoactive 
peptides of the RAS axis, proliferation was restored. Similar beneficial responses were 
observed in cells from mice with nine months of diabetes (Figure 2B). Migratory function to 
the mouse chemoattractant CXCL12 was also reduced in LK cells from ACE2-/y-Akita mice 
with nine months’ duration of diabetes. However, migratory function was restored when 
cells were pretreated with Ang-1–7 or alamandine and then exposed to CXCL12 (Figure 2C 
and D).
Loss of ACE2 worsens diabetes-induced myelopoiesis and reduction of lymphopoiesis
Myelopoiesis was observed in the Akita and ACE2-/y-Akita mice at 9 months of diabetes as 
demonstrated by an increase in colony forming units (CFU)-Granulocyte/Macrophage/GM 
(G/M/GM) (Figure 3A). Common lymphoid progenitors (CLPs) are daughter cells of 
HS/PCs that are able to differentiate into lymphoid lineages (Figure 3). Phenotypic CLP 
markers are lineage-CD127+Sca-1medc-Kitmed. The percentage of CLPs was decreased in 
Akita mice compared to WT mice at the 9-month time point. A further reduction of CLP 
percentage was observed in the ACE2-/y-Akita mice when compared to Akita alone (Figure 
3C). These data suggested that diabetes resulted in lymphopoiesis. ACE2 deficiency further 
worsened the diabetes-mediated changes in hematopoiesis. These data suggest that diabetes 
results in a shift of hematopoiesis towards myelopoiesis, together with an impairment of 
lymphopoiesis. ACE2 deficiency further worsened the diabetes-mediated changes in 
hematopoiesis.
Diabetic mice exhibit reduced retinal thickness
Retinal thickness was assessed by OCT in each of the four cohorts (Figure 4A). Retinas in 
the Akita and ACE2-/y-Akita groups (~9.2% reduction) were thinner in comparison to WT 
and ACE2-/y mice, suggesting this effect was not the result of loss of ACE2 (Figure 4B) but 
rather diabetes.
When examining the central and peripheral retina by fundus photography, we observed that 
loss of ACE2 led to a dramatic increase in the number of white lesions in the retina, which 
may represent retinal nerve fiber layer infarcts (Figure 4C and D). These retinal changes 
occurred irrespective of diabetes suggesting that they were due to loss of ACE2.
ACE2-/y-Akita showed a progressive reduction in retinal electrical responses over the 
duration of diabetes
The electroretinogram (ERG) measures the electrical responses of distinct retinal cell types 
and provides information about retinal function with scotopic a-waves representing the 
electrical signal of rod photoreceptors and scotopic b-waves reflecting depolarizing bipolar 
cells and Müller cells [35]. At 3 months of diabetes, the Akita and the ACE2-/y-Akita 
cohorts demonstrated similar scotopic a- and b- wave amplitudes when compared to WT and 
ACE2-/y cohorts with the exception that Akita mice had a slight increase of a-wave 
amplitude compared to ACE2-/y mice. At 9 months of diabetes, Akita mice showed reduced 
scotopic b-wave but no change in a-wave when compared to WT mice (Figure 5). In 
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addition, only the loss of ACE2 in the presence of diabetes caused a reduction of both 
scotopic a- and b-waves, suggesting ACE2 ablation worsen diabetic retinal function.
Retinal microvascular complications in ACE2-/y-Akita mice
The hallmark feature of diabetic microvascular dysfunction is an increase in the number of 
acellular capillaries, defined as basal membrane tubes lacking endothelial cell and pericyte 
nuclei. At 9 months of diabetes, there was a significant increase in acellular capillary 
numbers in the Akita mice and ACE2-/y-Akita mice as compared to WT, with the double 
mutant showing a greater (1.6 fold) increase than Akita. (Figure 6 A, B). These data suggest 
that the ACE2 loss exacerbates this retinal microvascular defect.
Migratory dysfunction of human bone marrow-wderived CD34+ cells is associated with 
diabetic retinopathy severity
Healthy subjects, diabetic with no microvascular complications or those with retinopathy 
were assessed for systemic levels of RAS peptides and for CD34+ cell function. The clinical 
characteristics of the healthy and diabetic subjects are summarized in Supplemental Table 1. 
The levels of Ang II were similar in diabetes with no complications, diabetics with 
retinopathy and healthy subjects. In healthy controls, Ang-1–7 levels were low (less than 2.4 
pg/ml). Ang 1–7 was similarly low in diabetics with retinopathy. However, levels were 
elevated in diabetic subjects protected from development of retinopathy despite a protracted 
history of diabetes (Figure 7A).
CD34+ cells are bone marrow-derived cells that are considered to be human HS/PCs with 
vascular reparative potential. We next accessed whether changes in the RAS axis in these 
cells is associated with development of retinopathy. Gene expression for MAS, the receptor 
for Ang-1–7, was increased in CD34+ cells from diabetics with no retinopathy while 
significantly reduced in those with retinopathy (Figure 7B).
CD34+ cells isolated from healthy subjects or diabetic patients with no complications 
migrated toward the chemoattractant, CXCL12, while cells from subjects with retinopathy 
exhibited impaired migration (Figure 7C). However, pretreatment of the cells with Ang-1–7 
and alamandine restored migration from cells of subjects with retinopathy (Figure 7C, D).
Discussion
In this report, we used both murine and human studies to assess the impact of the protective 
RAS on bone marrow HS/PCs and development of retinopathy. Using ACE2-/y-Akita mice, 
we showed that loss of ACE2 expression worsens diabetes-induced bone marrow defects as 
demonstrated by a reduction in the numbers of the ST-HSCs and LT-HSCs, increased 
myelopoiesis and diminished common lymphoid progenitors, and impaired migration and 
proliferation of HS/PCs that was corrected by pretreatment with Ang1–7 or alamandine. 
ACE2-/y-Akita mice exhibited a greater number of acellular capillaries compared to Akita 
mice.
In human subjects, defects were observed in bone marrow-derived CD34+cells isolated from 
subjects with retinopathy. Reduced migratory function was corrected by the exogenous 
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supplementation of Ang-1–7 or alamandine. Serum Ang-1–7 levels were elevated in diabetic 
subjects with no retinopathy, but reduced in subjects with DR. Gene expression for MAS, 
the receptor for Ang-1–7, was increased in CD34+ cells from diabetics with no retinopathy 
but was significantly reduced in those with retinopathy. Collectively, these results support 
the critical role of sustained activation of the protective RAS in bone marrow cells for the 
prevention of retinopathy.
Bone marrow cells influence vascular repair, blood flow and endothelial barrier integrity by 
paracrine mechanisms [42]. Extensive literature supports that in chronic diabetes bone 
marrow cells become dysfunctional and are unable to support the function of the vasculature 
or repair injury [31, 41, 43–48]. Circulating angiogenic cells, although a small percentage of 
all circulating cells derived from bone marrow HS/PCs, exert robust vascular protective 
effects largely mediated by their production of growth factors and cytokines [42]. These 
factors are vasomodulatory and can mediate changes in vascular reactivity as well as 
maintain barrier characteristics of the endothelium [49]. However, circulating angiogenic 
cells of diabetics, such as CD34+ cells, typically lose this ability and secrete 
proinflammatory and vasoconstrictive factors [42, 50]. Additionally, diabetic circulating 
angiogenic cells lose their ability to migrate into tissues in response to local injury [31, 51–
53].
In this study, we saw that the levels of ACE2 mRNA in CD34+ cells isolated from peripheral 
blood of diabetic individuals predicted the in vitro function of these cells and directly 
correlated with the development of retinopathy. As described above, ACE2 generates 
Ang-1–7, which mediates the beneficial effect of ACE2. Ang-1–7’s effect is dependent on 
MAS receptor expression. We have observed that Ang-1–7 can enhance the migratory 
function of circulating angiogenic cells in vitro [25]. Ang-1–7 overexpression by lentiviral 
gene modification restored in vitro vasoreparative function of diabetic CD34+ cells and “in 
vivo” homing efficiency to areas of ischemia [25]. Genetic ablation of MAS prevented 
ischemia-induced mobilization of bone marrow cells thereby impairing blood flow recovery 
[54, 55].
In the current study, we demonstrated that the peptide alamandine beneficially impacts the 
migration of dysfunctional CD34+ from diabetics with retinopathy. Thus, these studies and 
others suggest that activation of the ACE2/Ang-1–7/MAS pathway stimulates the function 
of dysfunctional murine and human bone marrow cells in diabetes [56]. Here we observed, 
for the first time, that alamandine has similar beneficial effects on HS/PC migration and 
proliferation functions as Ang-1–7 in both diabetic mouse model and human subjects. 
Alamandine is a newly found peptide in the protective RAS axis and is also generated by 
ACE2 [57]. Alamandine and Ang-1–7 are both composed of 7 amino acids. Alamandine 
differs only by one N-terminal amino acid from Ang-1–7. Unlike Ang-1–7 binding to MAS 
receptor, alamandine binds to a different receptor, the MAS-related G protein coupled 
receptor, membrane D (MRGPRD) [57]. The downstream signaling pathways of MAS 
involve activation of phosphatidylinositol 3-kinase (PI3K)/Akt and Slit3/ROCK [25, 55]. It 
is not known whether alamandine/MRGPRD share the same signaling pathway with Ang-1–
7/MAS. It is important to investigate in the future the underlying mechanisms of the 
beneficial effects of almandine on HS/PC functions.
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Another novel finding we observed is that loss of ACE2 in diabetes not only caused a 
profound depletion of ST- and LT-HSCs, but also resulted in an imbalance of myelopoiesis 
and lymphopoiesis. It is well established that long standing diabetes causes a shift of 
hematopoiesis towards enhanced myeloid cell production in both type 1 and type 2 diabetic 
model, which can drive the production and activation of proinflammatory cells [58, 59]. 
Although several factors are suggested to play a role in this pathological change, including 
hyperglycemia, leptin deficiency, and impaired cholesterol efflux [58, 60], the underlying 
molecular mechanisms remain unclear. This study, to our best knowledge, verifies for the 
first time that the protective RAS serves as a novel mechanism in the maintenance of the 
balance of myelopoiesis/lymphopoiesis in diabetes, thereby adding new perspectives to the 
understanding of pathological mechanisms of diabetes on the generation of bone marrow 
defects.
Diabetes and hyperglycemia result in an increased influx of proinflammatory cells into the 
retina and secretion of cytokines by the retina [61, 62]. Activation of myelopoiesis in the 
diabetic bone marrow leads to increased monocytes in the circulation. Myeloid-derived 
monocytes/macrophages then infiltrate into the diabetic retina, causing leukostasis, which 
can lead to occlusion of retinal capillaries [63–65]. Bone marrow-derived monocytes can 
also activate resident microglia, Müller glia and astrocytes in the retina by secreting 
proinflammatory cytokines, which further exacerbate retinal inflammation and can lead to 
retinal vaso-degeneration [66–69].
Previously, we showed that bone marrow dysfunction and bone marrow neuropathy precedes 
the development of retinopathy and that HSC are released in a circadian manner that is 
altered in diabetes [41]. However, when only measuring one time point as in this study, 
levels of LSK cells were similar between diabetic and nondiabetic groups. Furthermore, 
since the blood has considerably fewer LSK cells than the bone marrow, it was not possible 
to fully characterize these cells into long term- and short term-HSCs as we did for the bone 
marrow. We also tried to identify the c-kit+ cells using retinal cross sections by 
immunofluorescence staining. However, the c-kit+ cells are extremely rare in the retina and 
we were unable to detect them using this approach. Previously, we have used gfp chimeric 
mice to identify the presence of bone marrow-derived cells in the retina but this approach 
detects all CD45+ cells not just the c-kit+ cells [51, 70–72].
The impact of the RAS on DR finds support in numerous reports that classic RAS 
components [prorenin, renin, angiotensinogen, angiotensin-converting enzyme (ACE)-1, 
angiotensin II (Ang II), and the Ang II type 1 receptor (AGTR1)] are significantly elevated 
in ocular tissues of diabetic patients [73, 74] and animals [29, 75]. Previously, we showed 
that retinopathy can be prevented/reversed in streptozotozin-induced diabetes by increasing 
retinal ACE2 using adenoassociated virus (AAV)-ACE2 [24, 29].
ACE inhibitors and AT1R antagonists attenuate retinal microvascular disease in diabetic 
rodents by decreasing vascular hyperpermeability, acellular capillaries, and the expression of 
angiogenic factors, such as vascular endothelial growth factor [76]. AT1R blockade 
decreased the incidence of diabetic retinopathy in individuals with T1D and improved mild 
and moderate diabetic retinopathy in those with T2D but not advanced retinopathy [77, 78]. 
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Lack of sufficient penetration of these agents across the blood-retinal barrier was deemed 
responsible for why suppression of the classic RAS fails to treat advanced disease [29]. 
These studies led to the notion that restoring the balance between the classic RAS and the 
vasoprotective RAS represents a viable strategy for controlling diabetic retinopathy in 
humans. Furthermore, we show, for the first time, that ACE2 plays a critical role in the 
protection of the neural retina. This protection may be due, in part, to regulation of HS/PCs. 
ERGs record the electrical responses of the neural retina. Scotopic a-waves represent the 
neural signal of the rod photoreceptors, while scotopic b-waves are mainly generated by the 
bipolar cells [79]. In several different retinal injury models, intravitreal administration of 
HS/PCs have been shown to improve ERG measurements [35, 80]. HS/PCs can have a 
beneficial effect on the neural retina by i) direct upregulation of genes involved in 
photoreceptor maintenance, phototransduction, and sensory perception [80, 81]; ii) 
suppression of proapoptotic gene expression, including caspase-3 [80]; and iii) reduction of 
oxidative stress [80]. We observed that ACE2 deficiency in the Akita mice resulted in a 
reduction of both the scotopic a- and b- waves. This change in the scotopic a- and b- waves 
was associated with a depletion and dysfunction of bone marrow HS/PCs. Moreover, A 
healthy retinal vasculature is required to maintain the function of the neural retina and 
HS/PCs serve a critical role in vascular repair.
In addition, ACE2 may affect the neural retina by other mechanisms than modulating HS/PC 
function. When we examined the mice using color fundus photography, both ACE2-/y and 
ACE2-/y-Akita mice had an increase in white lesions, which we interpret as nerve fiber layer 
infarcts. No lesions were observed in the Akita mouse. This result suggests that the loss of 
ACE2 may be responsible for the observed neural layer changes and that ACE2 is needed 
for protection against development of these lesions.
Conclusion
In conclusion, we found that loss of ACE2 worsened diabetes-induced bone marrow changes 
and accelerated the progression of retinopathy. The phenotypic pathology observed in the 
bone marrow-derived cells of ACE2-/y-Akita mice was also found in CD34+ cells of diabetic 
human subjects with diabetic retinopathy. Diabetes-induced migratory and proliferative 
dysfunction could be corrected by exogenous administration of the RAS peptides Ang-1–7 
and alamandine. Our studies support that enhancing ACE2 or Ang 1–7 or alamandine could 
represents a potential therapeutic option for diabetic retinopathy.
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Significance Statement:
Hematopoietic stem/progenitor cells (HS/PC) have garnered attention for their vaso-
reparative potential. Longstanding diabetes is associated with HS/PC depletion and 
dysfunction. Performing both murine and human studies, we tested the hypothesis that 
the deficiency of ACE2, the key enzyme in the protective axis of the RAS would promote 
development of diabetic retinopathy by worsening diabetes-induced bone marrow HS/PC 
dysfunction. Our findings support that sustained activation of the protective RAS in bone 
marrow cells will prevent of development of retinopathy.
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Figure 1. Reduction of both short-term (ST-) and long-term repopulating (LT-) hematopoietic 
stem cells (HSCs) in bone marrow from ACE2-/y-Akita mice at 9 months of diabetes.
(A): Random glucose levels were increased in both Akita and ACE2-/y-Akita groups (n = 7–
9 per group). (B): Diabetic groups showed consistent low body weight, while the 
nondiabetic mice had increased body weight over time (n = 9–18 per group). (C): 
Representative scheme of gating for flow cytometry studies enumerating HSCs in each of 
the four cohorts, WT, ACE2-/y, Akita, ACE2-/y-Akita. (D): The percentage of ST-HSCs was 
decreased in ACE2-/y-Akita mice at 9-month time point (n = 12–22). (E): The percentage of 
LT-HSCs was reduced in the bone marrow of Akita mice compared to WT mice at 9-months. 
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Loss of ACE2 further decreased the diabetes-induced reduction of LT-HSC enumeration at 
9-month time point (n = 12–22). * p<0.05, as compared to WT; # p<0.05, as compared to 
ACE2-/y; & p<0.05, as compared to Akita; ** p<0.05, as compared to 3-month time point. 
Abbreviations: WT, wild type; ST-HSC, short-term repopulating hematopoietic stem cell; 
LT-HSC, long-term repopulating hematopoietic stem cell; 3 mon, 3 months of diabetes and 
age-matched control; 9 mon, 9 months of diabetes and age-matched control.
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Figure 2. Depletion of ACE2 worsens diabetes-mediated impairment of HS/PC proliferation and 
migration functions.
(A): Impaired proliferative function of HS/PCs was observed in Akita mice as early as 3 
months of diabetes. Loss of ACE2 further reduced proliferation (n = 5–7). (B): Absence of 
ACE2 exacerbated diabetes-induced impairment of HS/PC proliferation, which was restored 
by the treatment of Ang-1–7 100nM or alamandine 100nM (n = 5–6). (C): Ang-1–7 or 
alamandine improved the migration of diabetic HS/PCs toward chemoattractant CXCL12 at 
3 months of diabetes (n = 4–6). (D): HS/PCs from ACE2-/y-Akita mice had no response to 
chemoattractant CXCL12. Ang-1–7 or alamandine partially restored the migration of the 
diabetic HS/PCs (n = 4–6). For A-B, * p<0.05, as compared to WT; # p<0.05, as compared 
to ACE2-/y; & p<0.05, compared to Akita; ** p<0.05, as compared to no treatment. For C-
D, * p<0.05, as compared to WT; # p<0.05, as compared to ACE2-/y; & p<0.05, as 
compared to Akita; ** p<0.05, Compared to no treatment; ***, Compared to CXCL12. 
Abbreviations: WT, wild type.
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Figure 3. Absence of ACE2 worsens diabetes-mediated imbalance in hematopoiesis.
(A): Colony forming unit (CFU) assay showed an increased number of CFU-G/M/GM when 
plating bone marrow cells and a decreased number of total CFUs when plating red blood 
cell-lysed blood cells. Loss of ACE2 exacerbated diabetes-mediated alterations in both bone 
marrow and blood CFU assay (n = 14–20). (B): Representative gating scheme for 
enumeration of common lymphoid progenitors (CLP) (Lineage-CD127+Sca-1medc-Kitmed). 
(C): The percentage of CLPs was reduced in Akita mice at 9-month time point. There was a 
further decrease in CLP percentage in ACE2-/y-Akita (as compared to Akita alone) (n = 13–
22). * p<0.05, as compared to WT; # p<0.05, as compared to ACE2-/y; & p<0.05, as 
compared to Akita. Abbreviations: CFU, colony forming units; BFU-E, burst-forming unit-
erythroid; CFU-G/M/GM, CFU-granulocyte/monocyte/granulocyte-monocyte; CFU-
GEMM, CFU-granulocyte/erythrocyte/monocyte/megakaryocyte; CLP, common lymphoid 
progenitors; WT, wild type.
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Figure 4. Reduced retinal thickness in Akita groups at 9 months of diabetes.
(A): Representative images of retina near the optic nerve by OCT. (B): Reduced retinal 
thickness was observed in both Akita and ACE2-/y-Akita mice at the 9-month time point 
when compared to non-diabetic groups (n = 8 per group). (C): Color fundus photography 
showed increased white lesions in both ACE2-/y and ACE2-/y-Akita groups (n = 4–5 per 
group). (D): Quantification of the number of white lesions per retina. * p<0.05, as compared 
to WT; # p<0.05, as compared to ACE2-/y; & p<0.05, as compared to Akita. Abbreviations: 
OCT, optical coherence tomography; WT, wild type.
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Figure 5. Reduced electrical responses of retinal cells to scotopic light flash in ACE2-/y-Akita 
mice.
(A): scotopic a-waves, which reflects the signal of rod photocurrents, did not change in 
Akita alone at 9 months of diabetes. Loss of ACE2 caused a decrease in scotopic a-wave 
amplitude in Akita mice at 9 months of diabetes (n = 5–7). (B): Both Akita mice and 
ACE2-/y-Akita mice exhibited a reduction of scotopic b-wave, indicating low electrical 
responses of depolarizing bipolar cells and Müller cells. Only ACE2-/y-Akita mice showed a 
reduction of both scotopic a- and b- wave over the duration of diabetes (n = 5–7). * p<0.05, 
as compared to WT; # p<0.05, as compared to ACE2-/y; & p<0.05, as compared to Akita; ** 
p<0.05, as compared to 3-month time point. Abbreviations: ERG, electroretinogram; WT, 
wild type.
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Figure 6. ACE2 ablation worsens diabetes-induced increase in acellular capillaries at 9 months of 
diabetes.
(A): representative images of retinal vasculature and acellular capillaries (arrow) from the 
different cohorts at both 3-month and 9-month time points. (B): Increased number of retinal 
acellular capillaries was observed in Akita mice. ACE2-/y-Akita mice had a further increase 
in acellular capillary number (as compared to Akita mice), suggesting more advanced 
retinopathy (n = 7–12 per group). * p<0.05, as compared to WT; # p<0.05, as compared to 
ACE2-/y; & p<0.05, as compared to Akita; ** p<0.05, as compared to 3-month time point. 
Abbreviations: WT, wild type.
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Figure 7. Loss of protective RAS axis and impaired migration function of HSPCs in diabetic 
subjects with non-proliferative diabetic retinopathy (NPDR).
(A): plasma Ang II and Ang-1–7 peptide levels in healthy control, diabetes with no 
complications (DM-NC), and diabetes with NPDR. Ang-1–7 level was increased in DM-NC 
followed by a reduction at NPDR stage (n = 5–10). (B): MAS, receptor for Ang-1–7 was 
also increased in CD34+ cells from DM-NC patients, but reduced in those from NPDR 
subjects (n = 5–17). (C): Impaired migration ability of CD34+ cells were observed at the 
NPDR stage, which can be restored by Ang-1–7 treatment (n = 6–14). (D): Alamandine 
treatment can also restore the migration function of CD34+ cells at both no complication and 
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NPDR stages (n = 4–8). For A and B, * p<0.05 as compared to control; & P<0.05 as 
compared to DM-NC. For C and D, * p<0.05 as compared to control; & P<0.05 as compared 
to DM-NC; ** p<0.05 as compared to CXCL12+Ang-1–7 or CXCL12+Alamd group; # 
p<0.05 compared to no treatment group. Abbreviations: DM-NC, diabetes with no 
complications; NPDR, non-proliferative retinopathy; Alamd, alamandine.
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